Scilex Holding Company entered into a worldwide exclusive license with Datavault AI to use its AI‑driven platform for tokenizing and monetizing biotech assets, including genomic data, diagnostics, therapeutics, and drug information.
The agreement centers on Datavault AI’s intellectual property, including the pending U.S. Patent Application No. 17/941,623 for “Platform and Method for Tokenizing DNA Data.” Scilex will pay a non‑refundable upfront license fee of $10 million, paid in four equal installments of $2.5 million on December 31, 2025; March 31, 2026; June 30, 2026; and September 30, 2026. Datavault AI will receive sales milestone payments totaling up to $2.55 billion upon reaching specified sales milestones.
The partnership positions Scilex to broaden its portfolio beyond pain‑management products. Management highlighted that tokenizing approximately $2 trillion in pharmaceutical drug sales and diagnostic sales could create a new non‑dilutive funding vehicle for biotech companies, potentially diversifying revenue streams and enhancing shareholder value. Scilex’s recent quarterly results showed net sales of $12 million for its flagship pain‑management product, a 20% increase from the same period last year, and the company remains compliant with Nasdaq’s minimum bid price requirements.
Datavault AI, a publicly traded data‑technology company, reported revenue of $150 million in 2024 and a net income of $12 million. The company’s platform leverages Web 3.0, blockchain, and AI technologies to monetize data assets. The new tokenization platform will allow fractional ownership of biotech assets, potentially improving liquidity for traditionally illiquid assets. The regulatory environment for tokenized real‑world assets is evolving, with the SEC and CFTC reviewing frameworks for digital asset securities, and the partnership will need to navigate these regulatory developments.
The biotech tokenization market is projected to grow rapidly, and competitors such as BioToken and GenomicChain are also developing similar platforms. Scilex and Datavault AI emphasized that the partnership will include robust compliance measures and will seek regulatory approvals as required. The collaboration aligns with Datavault AI’s strategy to monetize its data and AI assets across industries and with Scilex’s goal to diversify beyond its core pain‑management portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.